Skip to Content

Trinity Biotech plc (NASDAQ: TRIB)

Securities Class Action

Overview
  • Date:
  • 1/5/2017
  • Company Name:
  • Trinity Biotech plc
  • Stock Symbol:
  • TRIB
  • Status:
  • Closed/Complete

Case Finder

Locate any case using the tools below.

NEW YORK, January 5, 2017 – Bragar Eagel & Squire, P.C. is investigating potential claims against Trinity Biotech plc (NASDAQ: TRIB) concerning possible violations of the federal securities laws.

On October 4, 2016, Trinity revealed that it was withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer, following the U.S. Food and Drug Administration’s advice. Trinity also said it would decrease its spending by roughly 85%, from $9 million each year to $1.5 million, and that it would close its Swedish facility, eliminating 40 jobs. Following this news, Trinity shares dropped $6.53 per share to close at $6.46 on October 4, 2016.

If you own Trinity securities or continue to hold shares purchased, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: